[6]Vergaro,G. et al.N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. European journal of heart failure,2023. 25(3):p.335-346. [7]Kittleson,M.M,et al.2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidiscip...
[7]Kittleson,M.M,et al.2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology,2023. 81(11):p. 1076-1...
[7]Kittleson,M.M,et al.2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology,2023. 81(11):p. 1076-1...
在ACC 2023年会上,STELLAR研究团队发布了关于sotatercept的3期临床试验结果,证明sotatercept可显著改善主要终点——肺动脉高压(PAH)患者的运动能力,并且改善患者总体情况、肺血管阻力、NT-proBNP水平、WHO功能分级、死亡或临床状况恶化等8项次要终点[63]。 该研究共入组323...
ACC 2023年会上,首个关于三尖瓣介入治疗的随机对照研究——TRILUMINATE研究结果也备受瞩目,继主动脉瓣领域PARTNER系列研究、二尖瓣领域EVEREST系列研究之后,研究者终于吹响了向三尖瓣介入进攻的号角[62]。研究共纳入350例有症状的重度三尖瓣反流、肺动脉收缩压低于70 mm Hg、正在接受稳定的(≥30天)指南指导的抗心衰...
然而,第一个患者可能患有HFpEF并伴有高血压、肥胖症、心房颤动和慢性肾脏病(chronic kidney disease,CKD)等合并症,而第二个患者的HFpEF很有可能是由一个特殊来源--转甲状腺素心脏淀粉样变(transthyretin cardiac amyloidosis)引起的,需要通过单克隆蛋白筛查(monoclonal protein screen)和焦磷酸锝扫描(technetium ...
71.Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023;389:1553-65. 作者介绍 霍勇,北京大学第一医院主任医师、教授。第十二届、十三届、十四届全国政协委员。现任世界华人心血管医师协会会长、亚洲心脏病学会主席、中国医师协会心...
2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll ...
心脏淀粉样变性(Cardiac Amyloidosis,CA)患者的总体CT-ECV值为50. 2%(95% CI 46. 2%-54. 2%),具有显著异质性(I2 = 88. 5%): 在几乎所有研究中,心脏淀粉样变性患者的CT-ECV都远远高于健康患者。 Deux等人的研究(Ref 57)表明: 心脏淀粉样变性的CT-ECV(54.7% ± 9.7%)高于非淀粉样蛋白性心脏肥大患者(...
1016jjacc 2018 05 065 57 SingulaneCC SlivnickJA Addetia K etal Prevalenceofright atrialimpairment and association with outcomes in cardiac amyloidosis J JAm SocEchocardiogr2022 35 8 829-835 e1 DOI101016jecho202203022 58 AnwerS GuastafierroF ErhartL etal...